In the BioHarmony Drug Report Database
Caplacizumab-yhdp
Cablivi (caplacizumab) is an antibody pharmaceutical. Caplacizumab was first approved as Cablivi on 2018-08-30. It has been approved in Europe to treat thrombotic thrombocytopenic purpura. The pharmaceutical is active against von Willebrand factor.
Trade Name
|
Cablivi |
|---|---|
Common Name
|
caplacizumab |
ChEMBL ID
|
CHEMBL2109624 |
Indication
|
thrombotic thrombocytopenic purpura |
Drug Class
|
Monoclonal antibodies: humanized, cardiovascular indications |
Image (chem structure or protein)
